Literature DB >> 20155437

Discrimination and evaluation of lactoferrin and delta-lactoferrin gene expression levels in cancer cells and under inflammatory stimuli using TaqMan real-time PCR.

Esthelle Hoedt1, Stephan Hardivillé, Christophe Mariller, E Elass, Jean-Paul Perraudin, Annick Pierce.   

Abstract

The lactoferrin gene is known to be expressed either constitutively or under inducible conditions such as hormonal stimuli or inflammation. Its transcription from alternative promoters leads to two products, lactoferrin (Lf) and delta-lactoferrin (DeltaLf) mRNAs the expressions of which are altered during oncogenesis. The comparison of the two enhancer/promoter regions revealed that the two isoforms might be differentially trans-activated. Nevertheless, concomitant expression of both transcripts has been found in some normal tissues and in a subset of breast cancer cell lines and biopsies. Moreover, we found putative inflammatory response elements in both P1 and P2 promoter regions suggesting that both Lf and DeltaLf might be upregulated under inflammatory stimuli. Therefore, a duplex Taqman gene expression assay has been developed and used to profile mRNA expression of the Lf gene in the case of cancer and under inflammatory conditions. Discrimination between the two transcripts is achieved by using a primer pairs/probe set within exon 1beta for DeltaLf and a primer pairs/probe set within exon 1 and exon 2 for Lf. In this study, we confirmed that Lf/DeltaLf Taqman gene expression assay is a powerful tool to investigate the expression of both Lf and DeltaLf transcripts. We also showed that lymphocytes and leukocytes isolated from fresh human blood expressed an extremely high level of DeltaLf messengers. An extensive series of cancer cell lines has been studied confirming that both P1 and P2 promoter regions of the Lf gene are downregulated or silenced in the case of cancer. Furthermore, using stimulation by bacterial lipopolysaccharides (LPS), we showed that in MDA-MB-231 and HT-29 epithelial cells, Lf expression is strongly increased with a higher expression level in MDA-MB-231 whereas DeltaLf expression is not. These results suggest that the NF-kappaB/cRel response elements present in the P1 promoter region are functional whereas those present in the P2 promoter region are not and show that DeltaLf is not regulated in inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20155437     DOI: 10.1007/s10534-010-9305-5

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   2.949


  7 in total

Review 1.  The Lactoferrin Phenomenon-A Miracle Molecule.

Authors:  Paweł Kowalczyk; Katarzyna Kaczyńska; Patrycja Kleczkowska; Iwona Bukowska-Ośko; Karol Kramkowski; Dorota Sulejczak
Journal:  Molecules       Date:  2022-05-04       Impact factor: 4.927

2.  Modification by SUMOylation Controls Both the Transcriptional Activity and the Stability of Delta-Lactoferrin.

Authors:  Adelma Escobar-Ramirez; Anne-Sophie Vercoutter-Edouart; Marlène Mortuaire; Isabelle Huvent; Stephan Hardivillé; Esthelle Hoedt; Tony Lefebvre; Annick Pierce
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

3.  SILAC-based proteomic profiling of the human MDA-MB-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin.

Authors:  Esthelle Hoedt; Karima Chaoui; Isabelle Huvent; Christophe Mariller; Bernard Monsarrat; Odile Burlet-Schiltz; Annick Pierce
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

4.  M860, a Monoclonal Antibody against Human Lactoferrin, Enhances Tumoricidal Activity of Low Dosage Lactoferrin via Granzyme B Induction.

Authors:  Ya Li; Jie Li; Zheng Gong; Xiao-Hua Pan; Zi-Han Ma; Shu-Yan Ma; Hong-Min Wang; Hong-Liang Dong; Fang-Yuan Gong; Xiao-Ming Gao
Journal:  Molecules       Date:  2019-10-09       Impact factor: 4.411

Review 5.  Lactoferrin from Milk: Nutraceutical and Pharmacological Properties.

Authors:  Francesco Giansanti; Gloria Panella; Loris Leboffe; Giovanni Antonini
Journal:  Pharmaceuticals (Basel)       Date:  2016-09-27

Review 6.  Lactoferrin's Anti-Cancer Properties: Safety, Selectivity, and Wide Range of Action.

Authors:  Antimo Cutone; Luigi Rosa; Giusi Ianiro; Maria Stefania Lepanto; Maria Carmela Bonaccorsi di Patti; Piera Valenti; Giovanni Musci
Journal:  Biomolecules       Date:  2020-03-15

7.  Plasmalemmal V-ATPase as a Potential Biomarker for Lactoferrin-Based Anticancer Therapy.

Authors:  Cátia Santos-Pereira; Lígia R Rodrigues; Manuela Côrte-Real
Journal:  Biomolecules       Date:  2022-01-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.